CP015
Research type
Research Study
Full title
Safety and Performance Evaluation of Seraph 100 Microbind Affinity Blood Filter (Seraph 100) in the reduction of pathogen load from the blood in septic patients with suspected, life-threatening bloodstream infection
IRAS ID
281040
Contact name
natascha de Jong
Contact email
Sponsor organisation
ExThera Medical Europe BV
Clinicaltrials.gov Identifier
Duration of Study in the UK
1 years, 3 months, 31 days
Research summary
The Seraph 100 Blood Filter is used to reduce the amount of pathogens in the blood during bloodstream infection. Bacteremia or bloodstream infection, also called BSI, occurs when a bacterial infection elsewhere in the body enters the bloodstream. This clinical condition can quickly become life-threatening and progress to sepsis. Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. When sepsis occurs with extremely low blood pressure, it’s called septic shock. Septic shock is fatal in many cases.
Sepsis can be triggered by many types of bacteremia although the exact source of the infection often cannot be determined. Some of the most common infections that lead to BSI are lung infections (i.e. pneumonia) and infections in the abdominal area. Patients who are already in the hospital for something else, such as a surgery, are at a higher risk of developing BSI. These infections are even more dangerous when the bacteria are already resistant to antibiotics.REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
20/YH/0124
Date of REC Opinion
1 Jun 2020
REC opinion
Further Information Favourable Opinion